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Abstract
Introduction Individuals deficient in mannose-binding lectin
(MBL), an important component of the innate immune system,
show increased susceptibility to infection. We investigated
whether polymorphisms in the MBL2 gene and the serum level
are associated with the severity and prognosis of sepsis.
Methods A total of 266 patients with sepsis and 398 healthy
controls were enrolled. We analyzed the three single nucleotide
polymorphisms (Gly54Asp, -550, and +4) in the MBL2 gene.
Serum samples collected on day 1 were analyzed for the levels
of MBL.
Results Patients who were heterozygous (A/B) or homozygous
(B/B) at codon 54 (adjusted odds ratio (OR), 0.370; 95%
confidence interval (CI), 0.207-0.661, P = 0.001) and who were
heterozygous (H/L) or homozygous (L/L) at -550 (adjusted OR,
0.476; 95% CI, 0.249-0.910, P = 0.025) were less likely to
have septic shock in the sepsis group. Using Cox regression
analysis for 28-day mortality, an MBL level ≥ 1.3 microg/mL
showed significantly lower 28-day mortality (P = 0.020; hazard
ratio, 0.571; 95% CI, 0.355-0.916) in the septic shock group.
Conclusions Homozygosity at codons 54 (A/A) and -550 (H/H)
appears to be associated with the severity, but not the outcome,
of sepsis, whereas a low MBL level may be an independent risk
factor for mortality. These findings suggest that the genotype
and serum level for MBL2 may have different clinical
implications.
Introduction
Severe sepsis and septic shock cause 30% to 50% of all
deaths in intensive care units (ICUs) [1]. Numerous studies
have suggested that individuals vary in their ability to resist
infection [2-4]. Genetic variations, such as those in the TNF-α
alleles, have been implicated in determining the susceptibility
to and outcome of sepsis [3,5-8]. The innate immune system
is activated prior to the acquired immune system, and is thus
the first line of defense against pathogens. The importance of
the interactions between pathogen-associated microbial pat-
terns and mannose-binding lectin (MBL) in activating innate
immunity has been considered as a component of the innate
immune system [9]. Moreover, it is now recognized that the
first response to invasion (i.e., innate immunity) has a signifi-
cant influence on the subsequent adaptive response [10,11].
MBL is a calcium-dependent collagenous lectin present in
serum. The high-molecular-weight oligomeric form of MBL
binds carbohydrates on the surface of bacteria, fungi, and par-
asites. MBL then mediates activation of the complement cas-
cade through MBL-associated serine proteases (MASP)-1
and -2, resulting in the destruction of microorganisms by
opsonization and direct complement-mediated death [12-14].
APACHE: Acute Physiology and Chronic Health Evaluation; bp: base pair; CI: confidence interval; ELISA: enzyme-linked immunosorbent assay; ICU: 
intensive care unit; IQR: interquartile range; MASP: MBL-associated serine proteases; MBL: mannose-binding lectin; M:F: male;female; OR: odds 
ratio; PCR: polymerase chain reaction; ROC: receiver operator characteristic; SNP: single nucleotide polymorphism; SOFA: Sequential Organ Failure 
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It has been reported that low concentrations of MBL cause
defects in opsonization and phagocytosis that have been
associated with recurrent infections in both infants and adults
[15-17]. Low serum levels of MBL have been correlated with
polymorphisms in the protein-coding region of MBL2 at
codons 52, 54, and 57, which encode the variant alleles D, B,
and C, respectively [18-20]. It was previously reported that
two MBL2 polymorphisms (MBL-2 exon 1 and promoter -221)
were associated with the development of sepsis, severe sep-
sis, and septic shock in Caucasian adults [21]. However, eth-
nic differences have been reported for both the promoter and
structural variants, and large inter-individual variations in the
level of MBL can be explained by the promoter variants [22].
Among Koreans, no polymorphisms in codons 52 and 57 have
been reported, whereas polymorphisms in MBL2 at codons
54, -550 (promoter), and +4 (5'-UTR) have been associated
with low MBL levels [23].
In this study, we investigated the relation between polymor-
phisms in MBL2 and the serum concentration of MBL, and
assessed whether these polymorphisms influence the severity
and prognosis of sepsis in a Korean population.
Materials and methods
Study population
Two hundred and sixty-six patients receiving intensive care for
sepsis between 1 May, 2004 and 31 December, 2006 were
enrolled in this study. All patients were managed according to
our sepsis management protocol, which was guided by three
full-time critical care physicians. All patients were older than
16 years of age (mean age ± standard deviation, 61.6 ± 14.7
years; male:female (M:F) = 169:97) and had been admitted to
the ICU of a university-affiliated hospital in Seoul, Korea. The
patients were divided into two groups: the severe sepsis
group (mean age 61.6 ± 16.9 years; M:F = 45:32) and the
septic shock group (mean age 61.6 ± 13.8 years; M:F =
124:65). The diagnosis of severe sepsis or septic shock was
based on the criteria presented at the American College of
Chest Physicians/Society of Critical Care Medicine Consen-
sus Conference in 1992 [see Additional data file 1] [24]. As
control subjects, 398 healthy blood donors (mean age 37.2 ±
14.2 years; M:F = 219:179) were recruited. Informed consent
was obtained from all study participants in accordance with
the policies of the Institutional Review Board. This study was
approved by the Institutional Review Board of the Asan Medi-
cal Center, Seoul, Korea.
Clinical data, including demographic details, the Sequential
Organ Failure Assessment (SOFA) score, the Acute Physiol-
ogy, Age, and Chronic Health Evaluation II (APACHE II) score
obtained at day one of severe sepsis or septic shock, and the
ICU outcome, were recorded for each patient. Blood samples
for MBL polymorphism and serum level were drawn within 24
hours of the onset of severe sepsis or septic shock
Single nucleotide polymorphism genotyping
We chose three single nucleotide polymorphism (SNPs; -550
in the promoter, +4 in the upstream region, and Gly54Asp in
the coding region), which had previously exhibited an associ-
ation with low MBL levels [23]. Genotyping was performed by
PCR and sequencing, as previously described [25]. Haplo-
type analysis (A/B at codon 54, H/L at -550, and P/Q at +4)
was performed to characterize the combined effects of the
polymorphisms [26].
The polymorphism of -550 in the promoter was amplified by
PCR in a 302 bp fragment: forward primer 5'-TTGCCAGT-
GGTTTTTGACTC-3' and reverse primer 5'-GTATCT-
GGGCAGCTGATTCC-3'. The two polymorphisms of +4 in
the upstream region and Gly54Asp were amplified by PCR in
a 386 bp fragment: forward primer 5'-AGTCACGCAGTGT-
CACAAGG-3' and reverse primer 5'-
AGAACAGCCCAACACGTACC-3'.
Quantification of MBL by double antibody sandwich 
ELISA
The serum MBL level was measured using a sandwich ELISA
(MBL-ELISA; Dobeel, Gyeonggi, Korea) according to a previ-
ously established protocol [23].
Statistical analysis
The descriptive results of the continuous variables were
expressed as medians with an interquartile range (IQR). All
categorical data were compared using chi-squared analysis or
a Fisher's exact test. Continuous data were compared using
the Kruskal-Wallis or Mann-Whitney U tests. A receiver oper-
ating characteristic (ROC) curve was used to evaluate the cut-
off values for the MBL level. A multiple stepwise logistic
regression model was used to evaluate the prognostic value of
the MBL level. The genotype frequencies were checked for
consistency among cases and controls separately with those
expected from the Hardy-Weinberg equilibrium [see Addi-
tional data file 2] using commercial software (SNP Alyze v 5.0;
Dynacom, Yokohama, Japan). The association between cases
and controls were examined by comparing allele and genotype
frequencies in different groups of subjects using a chi-squared
test. Allelic frequencies were compared between cases and
controls using logistic regression to calculate age, gender-
adjusted odds ratios (OR), and 95% confidence intervals (CI).
Logistic regression analysis was also conducted to examine
any significant association between polymorphism and dis-
ease phenotype (disease site and behavior). The pairwise link-
age disequilibrium (LD) values, D', R2, and P  values
corresponding to chi-squared tests were calculated using the
SNP Alyze software package (SNP Alyze v 5.0; Dynacom,
Yokohama, Japan). The same software was used to estimate
haplotypes and their frequencies. SNP Alyze software uses an
expectation-maximization algorithm that determines the maxi-
mum-likelihood frequencies of multi-locus haplotypes in dip-
loid populations. To examine differences in individualAvailable online http://ccforum.com/content/13/6/R176
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haplotype frequency and overall haplotype profiles between
cases and controls, a permutation test was performed using
the SNP Alyze software. In addition, P values were calculated
by chi-squared statistics derived from simple two by two
tables based on the frequency of each haplotype versus all
others combined between cases and controls.
Results
Demographics of the subjects
The characteristics of the patients at the time of admission are
shown in Table 1. The overall mortality rate at 28 days was
31.4%. The severe sepsis group had a lower SOFA score and
lower mortality rate compared with the septic shock group
(10.6% vs. 39.7%; P < 0.001).
The association of the MBL2 gene polymorphisms with 
sepsis susceptibility
Patients who were heterozygous (A/B) or homozygous (B/B)
for the polymorphism at codon 54 (adjusted OR, 0.370; 95%
CI, 0.207 to 0.661, P = 0.001) were less likely to have septic
shock in the sepsis group (Table 2). Those patients in the sep-
sis group who were heterozygous (H/L) or homozygous (L/L)
at -550 (adjusted OR, 0.476; 95% CI, 0.249 to 0.910, P =
0.025) were less likely to have septic shock (Table 3). The fre-
quencies of P/Q at +4 were not significantly different among
the three groups (data not shown).
The association of serum MBL levels with the MBL2 
genotypes
The distribution of MBL concentrations was closely associ-
ated with the various MBL2 genotypes. The HH, HL, and LL
genotypes of the -550 polymorphism and the AA, AB, and BB
genotypes of the codon 54 polymorphism were correlated
with high, medium, and low MBL levels, respectively, in all
three groups, whereas the QQ, PQ, and PP genotypes of the
+4 polymorphism were correlated with high, medium, and low
MBL levels, respectively, only in the control group (Table 4).
The serum MBL level was different among the three groups,
even for subjects with the same genotype. Among the sub-
jects with genotype HL/LL at -550 and PP at +4, the serum
MBL level was higher for those in the septic shock group than
for those in the severe sepsis group (Table 4).
We next analyzed the haplotype profiles to characterize the
combined effects of the three polymorphisms. HPA/HPA,
HPA/LPA, and HPA/LQA were high MBL-producing haplo-
types, and their frequencies were similar among the three
groups. For subjects with the HPA/LPA haplotype, the serum
MBL level was higher for those in the septic shock group than
for those in the severe sepsis group (P < 0.05). The serum
MBL level in the control group was higher than the severe sep-
sis group for subjects with the HPA/LPA or LPA/LQA haplo-
types (P < 0.05) and lower than the severe sepsis group for
subjects with the HPA/LPB haplotype (P < 0.05) (Figure 1).
The association of serum MBL levels with outcome
The serum MBL level in the septic shock group (1.85 μg/mL;
IQR, 0.87 to 2.67) was higher (P < 0.05) than the severe sep-
sis (0.78 μg/mL; IQR, 0.39 to 1.37) or control groups (1.36
μg/mL; IQR, 0.39 to 2.74); however, the serum MBL level was
not significantly different between the severe sepsis and con-
trol groups. Subgroup analysis of the septic shock group indi-
cated that the survivors in this group (2.18 μg/mL; IQR, 1.15
to 2.95) had a higher serum MBL level (P < 0.05) than the non-
survivors (1.37 μg/mL; IQR, 0.49 to 2.05) (Figure 2). We
divided the septic patients into two groups according to serum
MBL levels (MBL <1.3 μg/mL and MBL ≥ 1.3 μg/mL) using a
ROC curve. There was no difference in frequency for Gram-
positive or Gram-negative infection depending on the MBL
deficiency. According to the Cox proportional hazards model,
a low MBL level (<1.3 μg/mL) was an independent risk factor
for mortality after 28 days within the septic shock group (Fig-
ure 3).
Discussion
Our study shows that two polymorphisms in MBL2 (at codons
54 in exon 1 and -550 in the promoter) may be associated with
the severity of sepsis in Korean patients; however, these poly-
morphisms were not associated with mortality. The serum
MBL level was associated with increased risk for mortality after
28 days in the patients with septic shock as found in previous
studies [21,27]. However, the serum MBL level was not deter-
mined through the known polymorphisms of MBL in the septic
condition.
MBL deficiency has been associated with infections in infants
and in patients with concomitant immunodeficiencies
[15,28,29]. Recent studies have reported that the frequency
of MBL-variant alleles is increased with the severity of sepsis
[21,27,30]. The functionality of the MBL-2 exon 1 and pro-
moter polymorphisms at -221 G/C, termed Y/X, has been well
documented in Caucasian patients [22,31,32]. To examine
the importance of MBL-variant alleles in the susceptibility to
sepsis among Korean patients, we analyzed three polymor-
phisms (-550, Gly54Asp, and +4) that had previously exhib-
ited significant correlations with the serum MBL level [23].
In the present study, the genotypes of individual SNPs were
not independently associated with the development of sepsis.
However, homozygosity for the MBL2 structural genotype (A/
A) and the -550 genotype (H/H) was associated with the pro-
gression from severe sepsis to septic shock. Due to selective
pressure promoting heterozygosity, a heterozygous advantage
(heterosis) of the MBL2-variant alleles has been proposed
[19,33]. The high frequency of MBL-variant alleles in different
populations indicates that these polymorphisms represent a
balanced genetic system favoring variant alleles arising from
genetic selection. Thus, the normal A allele may confer disad-
vantages to the host under some circumstances, such as sep-
sis [34]. Although heterozygosity associated with a low MBLCritical Care    Vol 13 No 6    Huh et al.
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Table 1
Baseline characteristics of the patients at day one of severe sepsis or septic shock
Characteristic Severe sepsis
(n = 77)
Septic shock
(n = 189)
P value
Age 65 (57-71) 65 (53-71) NS
Male gender, % 58.4 65.6 NS
APACHE II score 19 (15-24) 26 (21-34) 0.000
SOFA score 9 (7-11) 13 (10-15) 0.000
Admission route, n (%) NS
Medical 73 (94.8) 167 (88.4)
Surgical
elective/emergent 3 (3.9)/1 (1.3) 18 (9.5)/4 (2.1)
Prior or preexisting disease, n (%) NS
Chronic liver disease 6 (7.8) 17 (9.0)
Chronic pulmonary disease 1 (1.3) 7 (3.7)
Congestive heart disease 2 (2.6) 4 (2.1)
Diabetes mellitus 5 (2.6)
Malignancy 14 (18.2) 44 (23.3)
Neurologic disease 5 (6.5) 10 (5.3)
Othersa 3 (3.9) 7 (3.7)
≥ 2 diseases 7 (9.1) 22 (11.6)
None 39 (50.7) 73 (38.6)
Type of infection, n (%) 0.034
Pneumonia 20 (26.0) 80 (42.3)
Intraabdominal infection 15 (19.5) 34 (18.0)
Biliary 20 (26.0) 19 (10.1)
Urinary tract infection 11 (14.3) 21 (11.1)
Bacteremia 2 (2.6) 4 (2.1)
Wound infection 5(6.5) 12 (6.3)
Othersb 4 (5.2) 19 (10)
Positive culture, n (%) 45.5 37.0 NS
Gram-negative 68.6 60.0
Gram-positive 17.1 31.4
Mixed 11.4 2.9
Anaerobe 2.9 2.9
Fungi 2.9
Mechanical ventilation, % 51.9 79.3 <0.0001
Renal replacement, % 9.1 31.2 <0.0001
Length of ICU stay, days 4 (3-9) 10 (6-19) <0.0001
Nosocomial infection, % 23.4 22.2 NS
Data are presented as the median and interquartile range (25% to 75%). a = rheumatologic disease, inflammatory bowel disease; b = cellulitis, 
meningitis, leptospirosis.
APACHE II = Acute Physiology, Age, and Chronic Health Evaluation II; ICU = intensive care unit; NS = not significant; SOFA = Sequential Organ 
Failure Assessment.Available online http://ccforum.com/content/13/6/R176
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Table 2
Genotype frequencies for Gly54Asp in mannose-binding lectin between patients and controls and between septic patients
Locus Allele Group
N (%)
Group
n (%)
OR
(95% CI)
P Adjusted ORa
(95% CI)
P
Sepsis Control
GG A 185 72.27 262 66.16
GA 64 25.00 115 29.04 0.788
(0.550, 1.129)
0.194 0.815
(0.507, 1.312)
0.400
AA B 7 2.73 19 4.80 0.522
(0.215, 1.266)
0.150 0.388
(0.127, 1.180)
0.095
GG 185 72.27 262 66.16
GA/AA 71 27.73 134 33.84 0.750
(0.532, 1.058)
0.102 0.742
(0.471, 1.167)
0.196
Septic shock Severe sepsis
GG A 144 77.84 41 57.75
GA 37 20.00 27 38.03 0.362
(0.199, 0.658)
0.001 0.368
(0.202, 0.672)
0.001
AA B 4 2.16 3 4.23 0.389
(0.084, 1.807)
0.228 0.381
(0.081, 1.794)
0.222
GG 144 77.84% 41 57.75%
GA/AA 41 22.16% 30 42.25% 0.365
(0.205, 0.650)
0.001 0.370
(0.207, 0.661)
0.001
a = The adjusted OR was adjusted for age and gender. CI = confidence interval; OR = odds ratio.
Table 3
Genotype frequencies for --550 in mannose-binding lectin between patients and controls and between septic patients
Locus Allele Group
n (%)
Group
n (%)
OR
(95% CI)
P Adjusted ORa
(95% CI)
P
Sepsis Control
GG H 77 30.20 124 31.16
GC 122 47.84 182 45.73 1.079
(0.749, 1.556)
0.682 1.060
(0.783, 3.598)
0.810
CC L 56 21.96 92 23.12 0.980
(0.633, 1.518)
0.929 1.333
(0.755, 2.355)
0.322
GG 77 30.20 124 31.16
GC/CC 178 69.80 274 68.84 1.046
(0.744, 1.472)
0.795 1.142
(0.734, 1.788)
0.555
Septic shock Severe sepsis
GG H 63 34.24 14 19.72
GC 85 46.20 37 52.11 0.479
(0.239, 0.957)
0.037 0.465
(0.231, 0.936)
0.032
CC L 36 19.57 20 28.17 0.381
(0.173, 0.840)
0.017 0.379
(0.171, 0.839)
0.017
GG 63 34.24 14 19.72
GC/CC 121 65.76 57 80.28 0.484
(0.254, 0.922)
0.027 0.476
(0.249, 0.910)
0.025
a = The adjusted OR was adjusted for age and gender. CI = confidence interval; OR = odds ratio.Critical Care    Vol 13 No 6    Huh et al.
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level showed an advantage for severity in the sepsis, there was
no demonstrable influence on outcome. Accordingly, MBL pol-
ymorphisms may play a key role in the severity of sepsis, but
they are not a determinant of the outcome.
In contrast, the serum MBL level in response to sepsis seems
to be related to the outcome. A MBL level of 1.3 μg/mL or
more was an independent factor in the survival of septic shock.
However, among patients with the same haplotypes, the
serum MBL level was different depending on the clinical set-
ting. This suggests that other factors, such as cytokine levels
or other alleles moving in tight linkage disequilibrium, may
affect the level of MBL during sepsis. These findings may help
explain why, despite the strong relation between MBL2
genetic variants and susceptibility to septic shock, there is no
evidence to date showing the influence of the MBL2 genotype
on clinical outcome.
Using MBL2 genotype analysis, several studies have shown
variations in ethnic-specific genetic structure as well as non-
genetic factors [18-20,27]. However, the observation that a
deficiency in the amount of functional MBL increases the
severity of sepsis has been made repeatedly [27,30]. There-
fore, measuring the serum MBL level may be important for the
prognosis of septic patients in a clinical setting.
There were certain limitations to the present study. It has been
reported that two promoter polymorphisms -550 and -221,
and coding variants at codon 52, 54, and 57 of the MBL gene
affect the MBL protein level in various populations. In more
than 100 Korean controls, the codon 52 and 57 polymor-
phisms were not present and the effect of the -550 promoter
SNP on MBL levels was stronger than that of the -221 pro-
moter SNP. The effect of the X allele at -221 did not reach sta-
tistical significance (P = 0.156) in the correlation between
MBL genotypes and MBL serum levels [23]. This could be
because of the low frequency of the X allele in Koreans, 0.11,
compared with 0.195 in the Danish population. As we
screened only three known polymorphisms based on these
results, we cannot rule out the possibility that the observed dif-
ferences in MBL concentration are at least partially under the
influence of additional polymorphisms. In addition, without
examining family samples for inheritance patterns, the accu-
racy of this method of inference is unknown.
Another limitation of our study was that we did not evaluate
patients without sepsis, such as patients with noninfectious
systemic inflammatory response syndrome. If we had included
patients with noninfectious systemic inflammatory response
syndrome, we may have been able to explain our results more
clearly and provide more support for the suggestion that there
Table 4
Correlation of SNPs in the mbl2 gene with the serum MBL level
Normal control Severe sepsis Septic shock
Loci Allele Genotype Median
(IQR)
μg/L
Pa Median
(IQR)
μg/L
Pa Median
(IQR)
μg/L
Pa
-550 H GG 2493
(1452--3992)
0.000 2250
(1285--4800)
0.000 2550
(2010--3945)
0.000
GC 955
(335--2626)
810
(600--1360)
1530bc
(860--2400)
LC C3 8 4
(0--1284)
340
(275--710)
640c
(300--1630)
Gly54
Asp
AG G2 2 4 9
(1333--3352)
0.000 1370
(825--3925)
0.000 2280
(1500--2800)
0.000
GA 315
(3--540)
460b
(335--695)
475b
(298--695)
BA A 0 2 7 0
(135-280)
270
+4 P CC 1039
(215--2668)
0.036 800
(430--1363)
0.367 1910bc
(1045--2635)
0.470
CT 2182
(1187--2826)
800
(370--4265)
1605
(488--3013)
Q TT 4823 2895
(830--4960)
3570
Data are expressed as the median and interquartile range (IQR; 25% to 75%). a = P-value based on the Kruskal--Wallis or Mann--Whitney U test. 
Statistical differences in the mannose-binding lectin (MBL) levels were analyzed according to genotype within each subgroup. b = P < 0.05 vs. the 
control group. c = P < 0.05 vs. the severe sepsis group. SNP = single nucleotide polymorphism.Available online http://ccforum.com/content/13/6/R176
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is an association of the homozygous MBL2 structural geno-
type (A/A) and the -550 genotype (H/H) with the progression
from severe sepsis to septic shock. However, there were very
few patients without infection or with sepsis without organ fail-
ure admitted to the medical ICU of the tertiary referral hospital.
Moreover, we measured MBL levels only once within the initial
24 hours of the septic course. This single measurement may
reduce the power of the MBL level in terms of a prognostic
factor. In addition, certain confounding factors, such as treat-
ment and duration of illness before admission to the ICU, were
not included in our analysis.
Conclusions
Our results showed that the genotype and serum level for
MBL2 may have different clinical implications, and suggest
that the patient with high MBL2 production responding to a
bacterial invasion may have better prognosis irrespective of
MBL2 gene polymorphism.
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Key messages
•  Homozygosity for the MBL2 structural genotype (A/A) 
and the -550 genotype (H/H) was associated with the 
progression from severe sepsis to septic shock.
￿  An MBL level of 1.3 μg/mL or more showed significantly 
lower 28-day mortality (P = 0.020; hazard ratio, 0.571; 
95% CI, 0.355 to 0.916) in the septic shock group.
￿  The genotype and serum level for MBL2 may have dif-
ferent clinical implications.
Figure 1
Comparison of serum MBL levels in various haplotypes in the three  groups Comparison of serum MBL levels in various haplotypes in the three 
groups. The serum MBL level in the severe sepsis group was lower 
than the control group or the septic shock group (P < 0.05) for sub-
jects with the HPA/LPA haplotype (a). The serum MBL level in the con-
trol group was lower than the severe sepsis group (P < 0.05) for 
subjects with the HPA/LPB haplotype (b) and higher than the severe 
sepsis group for subjects with the LPA/LQA haplotypes (c). Haplotype 
estimation was performed using Arlequin software. The median man-
nose-binding lectin (MBL) levels are indicated by horizontal bars. * P < 
0.05 between the two groups.
Figure 2
The serum MBL levels in the control group and in the patients with  severe sepsis and septic shock The serum MBL levels in the control group and in the patients with 
severe sepsis and septic shock. The serum mannose-binding lectin 
(MBL) level in the septic shock group was higher than the severe sep-
sis or control group. The survivors had a higher serum MBL level than 
the nonsurvivors in the septic shock group. Data are expressed as the 
median and interquartile range (IQR). The box represents the median 
and IQR (25% to 75%) and the error bar represents the IQR (10% to 
90%).Critical Care    Vol 13 No 6    Huh et al.
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